Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNMD 
Mind Medicine Inc (MNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MNMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $25
1 Year Target Price $25
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.18% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 726.64M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 11 | Beta 2.97 | 52 Weeks Range 4.70 - 11.02 | Updated Date 09/15/2025 |
52 Weeks Range 4.70 - 11.02 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.55% | Return on Equity (TTM) -59.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 576468181 | Price to Sales(TTM) - |
Enterprise Value 576468181 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.57 | Shares Outstanding 76087904 | Shares Floating 70245911 |
Shares Outstanding 76087904 | Shares Floating 70245911 | ||
Percent Insiders 0.84 | Percent Institutions 55.72 |
Upturn AI SWOT
Mind Medicine Inc
Company Overview
History and Background
Mind Medicine (MindMed) Inc. was founded in 2019. It is a biopharmaceutical company developing psychedelic-inspired medicines to treat brain health disorders.
Core Business Areas
- Drug Development: Focuses on researching, developing, and commercializing psychedelic-inspired medicines.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Robert Barrow serves as CEO. The company has a board of directors overseeing operations.
Top Products and Market Share
Key Offerings
- MM-120 (Lysergide D-Tartrate): A proprietary formulation of LSD being developed for generalized anxiety disorder (GAD) and other disorders. Data indicates significant therapeutic benefit, however, this product is still in clinical trials. Competitors in anxiety treatments include traditional pharmaceuticals like SSRIs and benzodiazepines from companies like Pfizer and Eli Lilly, as well as other companies developing novel therapies.
- MM-402 (R-MDMA): R-MDMA, a synthetic enantiomer of MDMA, may have advantages over racemic MDMA in that it is potentially less toxic, non-hallucinatory, and possesses prosocial and anxiolytic properties. Competitors include companies researching MDMA-assisted therapy.
Market Dynamics
Industry Overview
The psychedelic medicine industry is emerging with increasing interest in alternative treatments for mental health disorders. There is growing acceptance of psychedelic-assisted therapies within research and medical communities.
Positioning
MindMed is positioned as a leading company in the psychedelic medicine space, focused on developing pharmaceutical-grade psychedelic-inspired treatments. They are trying to differentiate themselves through rigorous clinical trials and proprietary formulations.
Total Addressable Market (TAM)
The TAM for mental health treatments is substantial and growing, estimated to be in the tens of billions of dollars globally. MindMed's positioning within the emerging psychedelic medicine niche allows it to capture a segment of this broader market.
Upturn SWOT Analysis
Strengths
- Strong IP portfolio around psychedelic-inspired medicines
- Experienced management team with expertise in drug development
- Advanced clinical trial programs
- Early mover advantage in the emerging psychedelic medicine space
Weaknesses
- High cash burn rate
- Reliance on regulatory approvals for drug commercialization
- Limited revenue generation in the near term
- Potential for adverse effects associated with psychedelic drugs
Opportunities
- Growing acceptance of psychedelic-assisted therapies
- Potential for breakthrough therapy designations from regulatory agencies
- Partnerships with pharmaceutical companies
- Expansion into new indications and geographies
Threats
- Regulatory hurdles and uncertainties
- Competition from other companies developing psychedelic medicines
- Negative public perception of psychedelic drugs
- Potential for generic competition
Competitors and Market Share
Key Competitors
- ATAI Life Sciences (ATAI)
- COMPASS Pathways (CMPS)
- GH Research (GHRS)
Competitive Landscape
MindMed faces competition from other companies developing psychedelic medicines, each with their own unique approaches and target indications. Differentiation through clinical trial design and IP protection will be critical.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of clinical trials and expansion of the drug development pipeline.
Future Projections: Future growth depends heavily on successful clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst projections are speculative at this stage.
Recent Initiatives: Recent initiatives include initiating Phase 2b trials for MM-120 in GAD and advancing the development of MM-402.
Summary
Mind Medicine is a development-stage biopharmaceutical company in the high-risk, high-reward psychedelic medicine space. Positive clinical trial results for MM-120 are promising. However, the company needs to manage its cash burn and navigate the regulatory landscape effectively to achieve long-term success, as well as face fierce competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share is estimated as these are emerging companies, and therefore hard to pinpoint.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mind Medicine Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-03-03 | CEO & Director Mr. Robert Barrow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.mindmed.co |
Full time employees 74 | Website https://www.mindmed.co | ||
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.